TY - JOUR
T1 - A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix
T2 - A Southwest Oncology Group Study
AU - Weiss, Geoffrey R.
AU - Green, Stephanie
AU - Hannigan, Edward V.
AU - Boutselis, John G.
AU - Surwit, Earl A.
AU - Wallace, Darryl L.
AU - Alberts, David S.
N1 - Funding Information:
This investigation was supported in part by the following PHS Co-operative Agreement grants awarded by the National Cancer Institute, DHHS: CA-22433, CA-37429, CA-03096, CA-04920, CA-13612, CA-35438, CA-35090, CA-35158, CA-35261, CA-35431, CA-37981, CA-35274, CA-35200, CA-35176, CA-12644, CA-37445, CA-12213, CA-35084, CA-03389, CA-351 17, CA-35178, CA-35226, CA-35128, CA-321012.
PY - 1990/12
Y1 - 1990/12
N2 - Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.
AB - Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.
UR - http://www.scopus.com/inward/record.url?scp=0025635642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025635642&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(90)90262-J
DO - 10.1016/0090-8258(90)90262-J
M3 - Article
C2 - 2258080
AN - SCOPUS:0025635642
VL - 39
SP - 332
EP - 336
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -